3 Reasons to Avoid NEO and 1 Stock to Buy Instead [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Is there a buying opportunity in NeoGenomics, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team's opinion, it's free Why Do We Think NeoGenomics Will Underperform? We're happy investors have made money, but we're cautious about NeoGenomics. Here are three reasons there are better opportunities than NEO and a stock we'd rather own. 1. EPS Trending Down We track the long-term change in earnings per share (EPS) because it highlights whether a company's growth is profitable. Sadly for NeoGenomics, its EPS declined by 3% annually over the last five years while its revenue grew by 10.4%. This tells us the company became less profitable on a per-share basis as it expanded. NeoGenomics Trailing 12-Month EPS (Non-GAAP) 2. Previous Growth Initiatives Have Lost Money Growth gives us insight i
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor TypesBusiness Wire
- NeoGenomics (NASDAQ:NEO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- NeoGenomics (NASDAQ:NEO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 2/17/26 - Beat
NEO
Sec Filings
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- NEO's page on the SEC website